Top Markets
#1 Wibx Wibx +8.04%
#2 Status Status +7.32%
#3 Decred Decred +5.88%
#4 aelf aelf +5.13%
#5 Humanity Humanity +4.81%
#6 MarsCoin MarsCoin +3.34%
#7 TRIA TRIA +3.25%
#8 Rei Rei +2.83%
#9 Bless Bless +2.73%
#10 rsERG rsERG +2.41%
Coin of the day
Wibx Wibx
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD
Classificação em ações #30829
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Preço da ação
$0.343985
Última sincronização: 2026-08-18
Valor de mercado
$15.40M
Variação (1 dia)
3.94%
Variação (1 ano)
-21.48%
País
BE
Negociar Celyad Oncology S.A. (CYAD)

Categoria

Healthcare
EPS de Celyad Oncology S.A. (CYAD)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Celyad Oncology S.A., o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da Celyad Oncology S.A. de 2026 até 2026
EPS no final de cada ano
Ano EPS Alterar
Não há dados suficientes para as datas fornecidas.
EPS de empresas semelhantes ou concorrentes
Empresa EPS Diferença de EPS País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $2.98 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE